Promising Water Stocks To Research – August 25th

CSX, Home Depot, and Tharimmune are the three Water stocks to watch today, according to MarketBeat’s stock screener tool. Water stocks are shares in companies whose core businesses involve sourcing, treating, distributing or managing water resources. They include utilities that supply fresh water, engineering firms that build pipelines and treatment plants, equipment makers for desalination and filtration, and specialists in wastewater management or water-rights trading. Investors often view water stocks as defensive assets with steady demand and growth potential in light of mounting global water scarcity and stricter environmental regulations. These companies had the highest dollar trading volume of any Water stocks within the last several days.

CSX (CSX)

CSX Corporation, together with its subsidiaries, provides rail-based freight transportation services. The company offers rail services; and transportation of intermodal containers and trailers, as well as other transportation services, such as rail-to-truck transfers and bulk commodity operations. It also transports chemicals, agricultural and food products, minerals, automotive, forest products, fertilizers, and metals and equipment; and coal, coke, and iron ore to electricity-generating power plants, steel manufacturers, and industrial plants, as well as exports coal to deep-water port facilities.

Home Depot (HD)

The Home Depot, Inc. operates as a home improvement retailer in the United States and internationally. It sells various building materials, home improvement products, lawn and garden products, and décor products, as well as facilities maintenance, repair, and operations products. The company also offers installation services for flooring, water heaters, bath, garage doors, cabinets, cabinet makeovers, countertops, sheds, furnaces and central air systems, and windows.

Tharimmune (THAR)

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).